KEGG   DRUG: Ravulizumab
Entry
D11054                      Drug                                   
Name
Ravulizumab (USAN/INN);
Ravulizumab (genetical recombination) (JAN);
Ultomiris (TN)
Product
ULTOMIRIS (Alexion Pharmaceuticals)
Formula
C6430H9888N1696O2028S48
Exact mass
144846.9337
Mol weight
144936.5781
Sequence
(A chain)
XVQLVQSGAE VKKPGASVKV SCKASGHIFS NYWIQWVRQA PGQGLEWMGE ILPGSGHTEY
TENFKDRVTM TRDTSTSTVY MELSSLRSED TAVYYCARYF FGSSPNWYFD VWGQGTLVTV
SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
SSGLYSLSSV VTVPSSNFGT QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE
GNVFSCSVLH EALHSHYTQK SLSLSLG
(B chain)
XVQLVQSGAE VKKPGASVKV SCKASGHIFS NYWIQWVRQA PGQGLEWMGE ILPGSGHTEY
TENFKDRVTM TRDTSTSTVY MELSSLRSED TAVYYCARYF FGSSPNWYFD VWGQGTLVTV
SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
SSGLYSLSSV VTVPSSNFGT QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE
GNVFSCSVLH EALHSHYTQK SLSLSLG
(C chain)
DIQMTQSPSS LSASVGDRVT ITCGASENIY GALNWYQQKP GKAPKLLIYG ATNLADGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQN VLNTPLTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(D chain)
DIQMTQSPSS LSASVGDRVT ITCGASENIY GALNWYQQKP GKAPKLLIYG ATNLADGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQN VLNTPLTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: A22-A96, A136-C214, A149^A205, A224-B224, A225-B225, A228-B228, A231-B231, A262-A322, A368-A426, B22-B96, B136-D214, B149-B205, B262-B322, B368-B426, C23-C88, C134-C194, D23-D88, D134-D194)
  Type
Peptide
Remark
Therapeutic category: 6399
ATC code: L04AJ02
Product: D11054<JP/US>
Efficacy
Immunomodulator, Anti-complement C5 antibody
  Disease
Paroxysmal nocturnal hemoglobinuria [DS:H01053]
Atypical hemolytic uremic syndrome [DS:H01434]
  Type
Monoclonal antibody
Comment
Treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS)
Target
C5 [HSA:727] [KO:K03994]
  Pathway
hsa04610  Complement and coagulation cascades
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AJ Complement inhibitors
     L04AJ02 Ravulizumab
      D11054  Ravulizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Complement Inhibitors
    Ravulizumab
     D11054  Ravulizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D11054  Ravulizumab (USAN/INN); Ravulizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Organismal systems
   Complement and coagulation
    C5
     D11054  Ravulizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11054
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11054
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11054
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11054
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D11054
Other DBs
CAS: 1803171-55-2
PubChem: 363669767
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system